Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Anticancer Agents : Design, Synthesis and Evaluation
| Anticancer Agents : Design, Synthesis and Evaluation |
| Autore | Chen Qiao-Hong |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 online resource (606 p.) |
| Soggetto topico | Medicine and Nursing |
| Soggetto non controllato |
1,2,3-triazole
2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide 3,6-dibromocarbazole 4-(pyridin-4-yloxy)benzamide 5-bromoindole 5-fluorouracil ABCB1 (P-glycoprotein) actin ADME allene amides/esters androgen receptor anti-cancer activity anti-neuroinflammation anti-ovarian cancer anti-tumor anticancer anticancer activity anticancer agent anticancer agents anticancer compounds antimitotic agents antioxidant activity antiproliferative activity antiproliferative agent antitumor antitumor activity apalutamide apoptosis aromatase benzimidazole benzofuran-pyrazole benzofurans beta-lapachone bivalency breast cancer c-Met carbazole cell cycle chemical synthesis chemoresistance chrysin analogues colchiceine colchicine amide colchicine analogs colchicine sulfonamide colon cancer computational docking coumarin crystal structure cyanopyridone cytotoxic activity cytotoxic properties cytotoxicity darolutamide DFT study dihydroartemisinin dihydropyranoindole docking docking studies drug discovery drug resistance E-stereoselective enzalutamide enzyme inhibition estrone derivatives flavonoid flavonoids gemcitabine HDAC inhibitors HeLa HepG2 hydrates hydrazine IGF-1R IL-12 immune modulation indoleamine 2,3-dioxygenase inflammation inhibitor K562 kinase inhibitor MCF-7 MDM2-p53 interaction migration mimetics molecular simulation MOLT-4 multidrug resistance (MDR) reversal N-substituted pyrazoline nanoparticles natural product neuroblastoma NIH3T3 o-nitro-benzyl organosilicon compounds ortho-quinones ovarian cancer overcoming drug resistance P-glycoprotein P-MAPA PARP inhibitor PARP-1 inhibition phenylpyrazolopyrimidine photoactivatable protecting groups PI3Ks PI3Kα inhibitor PI3Kδ inhibitors polyvalency prodrug prostate cancer PROTACs protein degradation protein kinase protein-protein interactions Pyrazole pyrazolopyridine pyridotriazine quinazolin-4(3H)-one quinazolin-4(3H)-thione regioselective salinomycin Schiff base SILA-409 (Alis-409) SILA-421 (Alis-421) Src substituted pyridine synergy synthesis Talazoparib tanshione IIA taxoids thiazolidinone Thienopyrimidine thienopyrimidinone thiocolchicine thiopene thioxotriazopyridine TLR signaling topoisomerase II inhibitor triazolothiadiazine triple-negative breast cancer tryptophan metabolism tubulin inhibitors tumor specificity urea virtual screening xanthones yeast-based assays zampanolide βIII-tubulin |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Anticancer Agents |
| Record Nr. | UNINA-9910557129103321 |
Chen Qiao-Hong
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Inhibiting PARP as a Strategic Target in Cancer
| Inhibiting PARP as a Strategic Target in Cancer |
| Autore | Kristin Zorn |
| Pubbl/distr/stampa | Frontiers Media SA, 2016 |
| Descrizione fisica | 1 online resource (97 p.) |
| Collana | Frontiers Research Topics |
| Soggetto topico | Medicine |
| Soggetto non controllato |
Cancer
combination therapy DNA Damage DNA reapir Homologous Recombination PARP inhibitor |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910220059703321 |
|
Kristin Zorn
|
||
| Frontiers Media SA, 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Integrating Clinical and Translational Research Networks-Building Team Medicine
| Integrating Clinical and Translational Research Networks-Building Team Medicine |
| Autore | Salgia Ravi |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 online resource (250 p.) |
| Soggetto topico | Medicine and Nursing |
| Soggetto non controllato |
academic and community oncology
academic cancer center actionable mutations adjuvant chemotherapy bladder cancer breast cancer cancer care plans cancer center cancer clinical trials cancer genetics cancer genomics cancer prevention clinical research clinical trials colorectal cancer community community oncology community practice concurrent chemoradiation therapy COVID-19 driver mutations Early Recovery After Surgery (ERAS) epithelial ovarian cancer ethnicity fast-and-frugal trees feeding tube dependency frontline treatment genetics counseling geriatric oncology HER2-directed therapy human papillomavirus immunotherapy integrated cancer care low-dose CT scans lung cancer lung cancer screening maintenance therapy minorities n/a national guidelines for screening and prevention next-generation sequencing non-small cell lung cancer older adults oncology medical home oncology pathways oropharyngeal cancer PARP inhibitor personalized medicine pharmaceutical aids to smoking cessation precisian medicine precision medicine race receptor tyrosine kinases recruitment renal cell carcinoma research small cell lung cancer smoking cessation supportive care pathways surgical debulking surgical pathways team medicine team science team-based care team-based medicine testing rates tobacco control translational research urothelial carcinoma value-based cancer care value-based care |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557124403321 |
|
Salgia Ravi
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||